Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study

Br J Dermatol. 2020 Dec;183(6):1126-1128. doi: 10.1111/bjd.19313. Epub 2020 Aug 26.

Authors

G E Molina^{1

2}, K L Reynolds^{1

3

4}, S T Chen^{1

2

3}

Affiliations

¹ Harvard Medical School, Boston, MA, USA.
² Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
³ Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
⁴ Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.

PMID: 32531797
DOI: 10.1111/bjd.19313

No abstract available

Publication types

Letter

MeSH terms

Cross-Sectional Studies
Humans
Immune Checkpoint Inhibitors*
Pemphigoid, Bullous* / chemically induced
Pemphigoid, Bullous* / diagnosis
Pemphigoid, Bullous* / drug therapy

Substances

Immune Checkpoint Inhibitors